Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma

Cancer Investigation

Volumn 20, Issue 7-8, 2002, Pages 914-921

  Utikal, Jochen ^a   Leiter, Ulrike ^a   Udart, Martin ^a   Kaskel, Peter ^a   Peter, Ralf Uwe ^a   Krähn, Gertraud M ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bcl 2; c myc; Coexpression; Malignant melanoma; Melanoma metastases

Indexed keywords

PROTEIN BCL 2;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MELANOMA; MITOGENICITY; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN METASTASIS; SKIN TUMOR;

DNA PRIMERS; HUMANS; IMMUNOENZYME TECHNIQUES; MELANOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; SKIN NEOPLASMS;

EID: 0036421606     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120005904     Document Type: Article

References (29)

1. MacKie, R.M. Incidence, risk factors and prevention of melanoma. Eur. J. Cancer 1998, 34, S3-S6.
2. Greenlee, R.T.; Murray, T.; Bolden, S.; Wingo, P.A. Cancer statistics. CA Cancer J. Clin. 2000, 50, 7-33.
3. Kraehn, G.M.; Schartl, M.; Peter, R.U. Human malignant melanoma - A genetic disease? Cancer 1995, 75, 1228-1237.
4. McDonnell, T.J. Cell Division Versus Cell Death: A functional model of multistep neoplasia. Mol. Carcinogenesis 1993, 8, 209-213.
5. Williams, G.T.; Smith, C.A. Molecular regulation of apoptosis: Genetic controls on cell death. Cell 1993, 74, 777-779.
6. Manning, F.C.; Patierno, S.R. Apoptosis: Inhibitor or instigator of carcinogenesis. Cancer Investig. 1996, 14, 455-465.
7. Reed, J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994, 124, 1-6.
8. Evan, G.I.; Whyllie, A.H.; Gilber, C.S.; et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69, 119-128.
9. Pendergast, G.C. Mechanisms of apoptosis by c-myc. Oncogene 1999, 18, 2967-2987.
10. Vaux, D.L.; Cory, S.; Adams, J.M. Bcl-2 gene promotes haematopoetic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335, 440-442.
11. Bissonnette, R.P.; Echeverri, F.; Mahboubi, A.; Green, D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992, 359, 552-554.
12. Fanidi, A.; Harrington, E.A.; Evan, G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992, 359, 554-556.
13. Garte, S.J. The c-myc oncogene in tumor progression. Crit. Rev. Oncog. 1993, 4, 435-449.
14. Ross, D.A.; Wilson, G.D. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br. J. Surg. 1998, 85, 46-51.
15. Chana, J.S.; Grover, R.; Wilson, G.D.; et al. The clinical significance of c-myc oncogene expression in melanomas of the scalp. Br. J. Plast. Surg. 1998, 51, 191-194.
16. Greulich, K.M.; Utikal, J.; Peter, R.U.; Krähn, G. C-MYC and nodular malignant melanoma: A case report. Cancer 2000, 89, 97-103.
17. Kraehn, G.M.; Utikal, J.; Udart, M.; et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br. J. Cancer 2001, 84, 72-79.
18. Leiter, U.; Schmid, R.M.; Kaskel, P.; et al. Dominance of anti-apoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch. Dermatol. Res. 2000, 292, 225-232.
19. Bargue, R.C.; Daniel, P.T.; Mapara, M.Y.; et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-a expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 1995, 60, 854-859.
20. Bergmann, R.; Lurie, M.; Kerner, H.; et al. Mode of c-myc protein expression in spitz nevi, common melanocytic nevi and malignant melanomas. J. Cutan. Pathol. 1997, 24, 219-222.
21. Korabiowska, M.; Brinck, U.; Mirecka, J.; et al. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. In Vivo 1995, 9, 433-438.
22. Grover, R.; Ross, D.A.; Wilson, G.D.; Sanders, R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br. J. Plast. Surg. 1997, 50, 478-482.
23. Grover, R.; Wilson, G.D. Bcl-2 Expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 1996, 22, 347-349.
24. Böni, R.; Bantschapp, O.; Muller, B.; Burg, G. C-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma. Dermatology 1998, 196, 288-291.
25. Alarcon, R.M.; Rupnow, B.A.; Graeber, T.G.; et al. Modulation of c-myc activity and apoptosis in vitro. Cancer Res. 1996, 56, 4315-4319.
26. Sarbia, M.; Loberg, C.; Wolter, M.; et al. Expression of bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. Am. J. Pathol. 1999, 155, 1027-1032.
27. Serrone, L.; Hersey, P. The chemoresistance of human malignant melanoma. An update. Melanoma Res. 1999, 9, 51-58.
28. Peltenburg, L.T.; Steegenga, W.T.; Kruse, K.M.; Schrier, P.I. C-myc-induced natural killer cell sensitivity of human melanoma cells is reversed by HLA-B27 transfection. Eur. J. Immunol. 1992, 22, 2737-2740.
29. Griffioen, M.; Peltenburg, L.T.C.; Van Oorschot, D.A.J.; Schrier, P.I. C-myc represses transiently transfected HLA class I promotor sequences not locus-specifically. Immunobiology 1995, 193, 238-247.